Hologic Inc

Hologic — Q1 2023 Earnings Presentation

38 slides from Hologic's earnings presentation, Feb 1, 2023

  1. Slide 1: Purpose Driven. Results Driven.

    Purpose Driven. Results Driven. February 2023 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking information that involves risks and uncertainties, including statements about the Company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or other

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures The Company has presented the following non-GAAP financial measures in this presentation: constant currency revenues; organic revenues; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP operating margin; non-GAAP effective tax rate; non-GAAP net income; non-GAA

  4. Slide 4: Presentation Outline

    Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 4

  5. Slide 5: Investment Thesis

    Investment Thesis • Purpose Driven, Results Driven • Commitment to purpose supercharges engagement and amplifies strength • Transformation into a much stronger Company than pre-pandemic ○ More diverse, recurring revenue ○ More long-term growth opportunities ○ More global ○ With stronger base busines

  6. Slide 6: Presentation Outline

    Presentation Outline Introduction Purpose Driven Results Driven Conclusion 6

  7. Slide 7: An Unparalleled Commitment to Women's Health

    An Unparalleled Commitment to Women's Health 7

  8. Slide 8: ESG Focus: Making a Unique Difference in the World

    ESG Focus: Making a Unique Difference in the World • Strong financial results enable us to live into our Purpose, Passion and Promise more fully than ever before • Driving meaningful change with the Hologic Global Women’s Health Index, Project Health Equality and our Global Access Initiative • Focus

  9. Slide 9: Our Purpose Creates A Unique Strength

    Our Purpose Creates A Unique Strength Together, we achieve MORE! 9

  10. Slide 10: Elevating Global Women's Health…

    Elevating Global Women's Health… …Through important social initiatives including: Hologic Global Women’s Health Index Project Health Equality Global Access Initiative 10

  11. Slide 11: Elevating Hologic's Company Profile…

    Elevating Hologic’s Company Profile… …By engaging world leaders, scoring big at the Super Bowl and partnering with the WTA — a global effort with global reach World Economic Forum Mary J. Blige & the Super Bowl Women’s Tennis Association 11

  12. Slide 12: Culture Creates Competitive Advantage

    Culture Creates Competitive Advantage Purpose + Results = World Class Engagement Engagement underpins our recognition as a highly Purpose underpins exceptional engagement ranked Top Workplace Stellar Engagement per Gallup Q12 Survey 2022 recognition as a Top Workplace at two of our largest employee

  13. Slide 13: Presentation Outline

    Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 13

  14. Slide 14: Hologic Overview

    Hologic Overview • Revenue of $4,863 million in fiscal 2022 By Division By Type By Geography Surgical Service 11% and Other 14% INTL 29% Capital 12% Breast and Diagnostics Skeletal 62% Consumables US 27% 74% 71% Note: Percentages in pie charts are for FY22. 14

  15. Slide 15: Strong Fiscal 2022 with Base Businesses Poised to Drive Growth…

    Strong Fiscal 2022 with Base Businesses Poised to Drive Growth… Total Revenue* 46.5% $6,000 $5,632 -12.3% $5,000 $4,863 12.1% $2,160 $4,000 5.7% $3,776 $1,431 8.3% 4.3% $3,218 $3,367 $3,059 $929 $3,000 9.9% 5.4% 0.4% $2,000 ** $1,000 $2,511 $2,705 $2,833 $2,851 $2,879 $3,052 $2,782 $3,473 $3,433 $0

  16. Slide 16: …And Deliver Robust Profitability

    …And Deliver Robust Profitability Non-GAAP EPS* $9.00 111.3% $8.00 $7.00 -28.4%** $6.00 $5.00 63.8% $4.00 $3.00 9.0% 3.6% 9.9% 17.4% $2.00 -2.7% 14.4% $1.00 $1.46 $1.67 $1.96 $2.03 $2.23 $2.43 $3.98 $8.41 $6.02 $0.00 2014 2015 2016 2017 2018 2019 2020 2021 2022 *Non-GAAP EPS as presented in our earn

  17. Slide 17: Generated $5 Billion in FCF over the Past 3 Years

    Generated $5 Billion in FCF over the Past 3 Years More than $3 Billion Deployed Since FY’20 M&A Accelerates Growth • Redeployed FCF* to drive growth across • 6 deals across each division the board ○ Diagnostics • Over $1.4 billion on M&A** – Biotheranostics, Diagenode, Mobidiag ○ Breast Health • Ove

  18. Slide 18: Strong Results to Start 2023

    Strong Results to Start 2023 Preliminary Q1’23 Q1’22 Change (CC) Revenue Revenue Diagnostics $559.3 $950.4 (39.4%) Organic Diagnostics $387.7 $345.5 15.8% excluding COVID Organic Molecular Diagnostics excluding $260.9 $214.8 24.5% COVID Breast Health $334.2 $359.3 (5.2%) GYN Surgical $154.1 $134.3 1

  19. Slide 19: Diagnostics Powered by Molecular…

    Diagnostics Powered by Molecular… Global Diagnostics* Revenue • Molecular Diagnostics drives Growth: + LDD Growth ○ ~3,250 Panther instruments globally as of $1,321 Q4’22 $1,029 ○ Menu adoption and utilization drive long-term growth $846 Millions $557 ○ Upside from COVID testing • Steadfast leadersh

  20. Slide 20: …With Improving Utilization Post-COVID…

    …With Improving Utilization Post-COVID… • Panther non-COVID utilization gaining traction* • Existing and new customers adding contracted non-COVID menu ○ ~ 85% of all New Customers** running at least one other assay in addition to COVID ○ ~ 55% of all New Customers** running at least two other assay

  21. Slide 21: …And a Broad Menu with More on the Way

    …And a Broad Menu with More on the Way FDA Approved Assays on Panther* • Menu in development for FDA 19 approval: ○ SARS-CoV-2/Flu/A/B/RSV ○ GI ○ GBS ○ EBV and BKV ○ C. Difficile 4 ○ M. gen resistance ○ Monkeypox 2014 2022 * Includes both Panther and Panther Fusion. 21

  22. Slide 22: Breast Health Recovery Through 2023…

    Breast Health Recovery Through 2023… • A more diverse and recurring business Breast Health Revenue $1,400 • 2023 sequential recovery in Mammography $1,200 ○ Breast Health constant currency revenue $1,000 45% (5.2%) in Q1’23 and up low-double digits for $800 38% the full-year $600 17% 25% • Intervent

  23. Slide 23: …with Leadership Across the Continuum of Care

    …with Leadership Across the Continuum of Care ARTIFICIAL INTELLIGENCE & ANALYTICS 23

  24. Slide 24: Robust Surgical Growth Continues

    Robust Surgical Growth Continues Global Surgical* Revenue • Stability in NovaSure +LDD Growth $522 • Continued strength in core MyoSure $437 • Underappreciated contribution from Fluent Fluid Management Millions • Strong growth in Laparoscopic portfolio: Acessa and Bolder • 14.7% constant currency or

  25. Slide 25: Strong Balance Sheet for Future Capital Deployment Opportunities

    Strong Balance Sheet for Future Capital Deployment Opportunities • Leverage well under 1x provides Net Debt and Leverage Ratio* $4.0 firepower for internal investment, tuck- $4.0 $3.5 in M&A, share repurchases 4.6x $3.1 $3.0 4.0x $2.8 $2.8 • No near-term debt maturities, $2.6 $2.5 3.3x 2.8x $2.3 no

  26. Slide 26: Presentation Outline

    Presentation Outline Introduction Purpose Driven Results Driven Conclusion and Financials 26

  27. Slide 27: Investment Thesis

    Investment Thesis • Purpose Driven, Results Driven • Commitment to purpose supercharges engagement and amplifies strength • Transformation into a much stronger Company than pre-pandemic ○ More diverse, recurring revenue ○ More long-term growth opportunities ○ More global ○ With stronger base busines

  28. Slide 28: Financial Overview Q1'23

    Financial Overview Q1’23 Non-GAAP $M, except EPS Q1’23 ∆ vs. Q1’22 Revenue $1,074.2 (27.0%) and (25.1%) CC Organic $1,062.5 (27.4%) and (25.5%) CC Organic ex COVID $898.2 3.8% and 6.4% CC Gross Margin 62.7% (940 bps) Operating Expenses $339.4 1.6% Operating Margin 31.1% (1,830 bps) Net Margin 24.9%

  29. Slide 29: Updated 2023 & Q2'23 Financial Guidance

    Updated 2023 & Q2’23 Financial Guidance Full Year* Q2’23* 2023 Guidance Q2’23 Guidance Revenue $3,850 – $4,000 $930 – $980 GAAP Diluted EPS $2.69 – $2.99 $0.60 – $0.70 Non-GAAP Diluted EPS $3.55 – $3.85 $0.80 – $0.90 Prior Full Year 2023 Guidance*: Revenue: $3,700 - $3,900 GAAP Diluted EPS: $2.51 -

  30. Slide 30: Appendix

    Appendix HOLOGIC' |

  31. Slide 31: COVID Assay and COVID-Related Revenue

    COVID Assay and COVID-Related Revenue COVID Assay and COVID-Related Revenue* $900 $823 $800 $78 $760 $700 $664 $80 $661 $600 $63 $596 $77 $514 $73 $500 $71 $400 $365 $352 $745 $41 $680 $61 $300 $601 $584 $523 $215 $187 $200 $443 $163 $42 $324 $291 $36 $36 $100 $173 $23 $27 $151 $127 $0 1Q20 2Q20 3Q2

  32. Slide 32: Non-COVID Panther Utilization Metrics

    Non-COVID Panther Utilization Metrics • Panther non-COVID utilization gaining traction: ○ + 90% of all customers running at least one other assay in addition to COVID ○ ~ 85% of all New Customers* running at least one other assay in addition to COVID ○ ~ 55% of all New Customers* running at least tw

  33. Slide 33: Capitalization as of Q1'23

    Capitalization as of Q1’23 Tranche Amount Leverage Coupon Rating Call Date Maturity Cash & Equivalents 2,441 Revolving Facility ($2,000 million) - SOFR + 110 Baa3 / BBB- 09/25/26 Term Loan 1,496 SOFR + 110 Baa3 / BBB- 09/25/26 Securitization program - NA 06/09/23 Total Secured Debt 1,496 0.9x Senior

  34. Slide 34: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended December 31, 2022 December 25, 2021 GROSS PROFIT GAAP gross profit $617.9 $986.3 Adjustments: Amortization of acquired intangible assets 55.6 74.9 Non-GAAP gross profit $673.5 $1,061.2 GROSS M

  35. Slide 35: Reconciliation of GAAP to Non-GAAP (unaudited)

    Reconciliation of GAAP to Non-GAAP (unaudited) $s in millions, except earnings per share Three Months Ended December 31, 2022 December 25, 2021 OPERATING MARGIN GAAP income from operations $262.4 $641.3 Adjustments to gross profit as detailed above 55.6 74.9 Adjustments to operating expenses as deta

  36. Slide 36: Reconciliation of GAAP to Non-GAAP EPS Guidance

    Reconciliation of GAAP to Non-GAAP EPS Guidance Guidance Range Quarter Ending April 1, 2023 Year Ending September 30, 2023 Low High Low High GAAP Net Income Per Share $0.60 $0.70 $2.69 $2.99 Amortization of acquired intangible assets $0.23 $0.23 $0.94 $0.94 Restructuring, Integration and Other charg

  37. Slide 37: Definitions

    Definitions • Organic Revenue: Total constant currency revenue excluding the divested Blood Screening business and revenue from acquired businesses owned by Hologic for less than one year. Revenue from acquired businesses is generally included in organic revenue guidance starting a year after the ac

  38. Slide 38: For More Information

    For More Information: Ryan Simon Francis Pruell VP, Investor Relations Senior Director, Investor Relations ryan.simon@hologic.com francis.pruell@hologic.com 38

Hologic — Q1 2023 Earnings Presentation on 6ix